CLEC4D and hemophilia A: The identification of preclinical animal models that better mimic the distribution of C-type lectin receptors in the human is necessary to confirm the reduced immunogenicity of FVIII2118Qin vivo, and its potential safety for replacement therapy in patients with hemophilia A.